Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Cedars-Sinai Medical Center
Nuvectis Pharma, Inc.
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Emory University
Blueprint Medicines Corporation
M.D. Anderson Cancer Center
University of California, Davis
Erasca, Inc.
Blueprint Medicines Corporation
Massachusetts General Hospital